XML 52 R38.htm IDEA: XBRL DOCUMENT
v3.24.2

Equity (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Stockholders' Equity Note [Abstract] |
Summary of the Warrants | A summary of the warrants is as follows:
|  | Number of shares |  |  | Exercise price |  |  | Expiration date |
Dragasac Warrant(1) |  |  | 652,981 |  |  | $ | 67.70 |  |  | March 16, 2025 |
Public Warrants(2) |  |  | 1,437,447 |  |  | $ | 115.00 |  |  | July 16, 2026 |
Sponsor Warrants(2) |  |  | 849,999 |  |  | $ | 115.00 |  |  | July 16, 2026 |
May 2022 PIPE Warrants |  |  | 405,405 |  |  | $ | 3.50 |  |  | October 10, 2028 |
March 2023 PIPE Warrants |  |  | 208,485 |  |  | $ | 30.00 |  |  | March 27, 2028 |
March 2023 PIPE Warrants (modified) |  |  | 729,698 |  |  | $ | 10.00 |  |  | March 27, 2028 |
March 2023 Loan Warrants |  |  | 75,000 |  |  | $ | 7.10 |  |  | March 17, 2028 |
April 2023 Registered Direct Warrants |  |  | 435,625 |  |  | $ | 7.50 |  |  | October 10, 2028 |
April 2023 Registered Direct Warrants (modified) |  |  | 487,451 |  |  | $ | 3.50 |  |  | October 10, 2028 |
May 2023 PIPE Warrants |  |  | 581,394 |  |  | $ | 10.00 |  |  | May 17, 2028 |
June 2023 Warrants |  |  | 50,000 |  |  | $ | 8.10 |  |  | June 20, 2028 |
June 2023 Loan Warrants |  |  | 300,000 |  |  | $ | 8.10 |  |  | June 20, 2028 |
July 2023 Registered Direct Warrants |  |  | 857,142 |  |  | $ | 3.50 |  |  | January 31, 2029 |
|  |  | 7,070,627 |  |  |  |  |  |  |
(1) The exercise price is the lesser of $67.70 per share or 80% of either (i) the value attributed to one share of Legacy Celularity Series B Preferred Stock upon consummation of a change in control or the closing of a strategic transaction or (ii) the price at which one share of common stock is sold to the public market in an initial public offering. (2) The number of Public Warrants and Sponsor Warrants outstanding was not adjusted for the reverse stock split. There are 14,374,478 Public Warrants and 8,499,999 Sponsor Warrants outstanding. After the reverse stock split, the number of warrants outstanding remains the same. However, each outstanding warrant is now exercisable for one-tenth of a share of Class A common stock, and the exercise price per share was adjusted to $115.00 as a result of the split.

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration